Invitae Corporation (NVTA)
(Delayed Data from NYSE)
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $36.66 in the latest trading session, marking a -1.5% move from the prior day.
Moving Average Crossover Alert: Invitae Corp (NVTA)
by Zacks Equity Research
Invitae Corporation (NVTA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Invitae (NVTA) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $35.96 in the latest trading session, marking a -0.39% move from the prior day.
Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $39.07, marking a -0.79% move from the previous day.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $34.45, moving -0.61% from the previous trading session.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $38.66, moving -0.46% from the previous trading session.
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -8.62% and 2.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $51.09, moving -1.64% from the previous trading session.
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $49.70, marking a -0.98% move from the previous day.
Invitae (NVTA) Stock Moves -0.96%: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $47.69, moving -0.96% from the previous trading session.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU
by Kevin Cook
Her focus on disruptive innovation broke the mold of Wall Street money management.
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -3.33% and 14.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
The Innovative Future Of ETFs
by Daniel Laboe
Ark Invest is driving a new generation of actively managed ETFs
Are Options Traders Betting on a Big Move in Invitae (NVTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -24.19% and 13.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $29.12, moving -1.59% from the previous trading session.
Analysts Estimate Invitae (NVTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.